The U.S. Food and Drug Adminstration (FDA) has just granted priority review to Gilead Sciences Inc.’s latest New Drug Application (NDA) for “Sofosbuvir”, an experimental drug candidate for the treatment of hepatitis C.
Sofosbuvir offers impressive cure rates among people suffering from genotype 2 and 3 HCV infection
hepatitis C
Sofosbuvir offers impressive cure rates among people suffering from genotype 2 and 3 HCV infection
hepatitis C
very positive patient response rates after three months therapy of sofosbuvir combined with ribavirin.
Sofosbuvir was found to offer much more effective treatment than Interferon.
Interferon can have quite severe side effectsheart failure
“The new sofosbuvir therapy offers a much-needed alternative to standard therapy with interferon, which can cause significant side effects for hepatitis C patients.
“We have dreamed for years of being able to eliminate interferon from our hepatitis C regimens and this study is one of several that are finally bringing us very close to realizing that goal.”
The study found that the longer the patients took the sofosbuvir combo, the higher their cure rate was.
“Given the absence to date of alternative therapies for patients with genotype 2 or 3 who have failed interferon therapy or for whom it is not an option, treatment with the new sofosbuvir regimen offers a vast improvement. But the optimal duration of treatment for genotype 3 patients, in order to maximize their chance of cure, remains undefined. It could be longer than 16 weeks.”